RxDoctor Payments Data

Eugenia Tsai, MD

Hepatology · San Antonio, TXNPI 1598028870

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (47.2%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 14 manufacturers reported payments, led by Astrazeneca UK Limited at 38.4% of the total. Reporting peaked in 2019 at $2,362 and has fallen 74.0% since, to $613 in 2025. That places this record below the midpoint for hepatology clinicians in TX, where the typical reported total is $8,956.

$5,619in general payments, 2019–2025

Across 81 payments — averaging $69.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astrazeneca UK Limited$2K
  • Novo Nordisk$2K
  • Mallinckrodt Hospital Products Inc.$358
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$279
  • Ipsen Biopharmaceuticals, Inc$234
  • Gilead$233
  • plus $800 from 8 others
$41,511in research payments, 2019–2025

Across 16 payments — averaging $2594.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Genentech, Inc.$42K

What the payments were for

  • Consulting fees$140%
  • Speaking & faculty fees$1,14320%
  • Travel & lodging$1,81232%
  • Food & beverage$2,65047%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,619 in reported general payments places this provider in the 45th percentile of 22 hepatology providers in Texas.

See all hepatology providers in Texas

Medicare billing

Part B allowed, 2024
$76,370
Medicare patients
297
Services billed
631

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Tacrolimus157$21,891
Valganciclovir Hcl57$11,804
ZarxioFilgrastim-Sndz25$11,299
EliquisApixaban13$7,683
Ursodiol68$6,552
Mycophenolate Mofetil45$4,762
Humalog Kwikpen U-100Insulin Lispro17$2,485
Lactulose59$1,714
Ultra-Fine Micro Pen NeedlePen Needle, Diabetic24$1,671
Midodrine Hcl11$1,497
ConstuloseLactulose59$1,197
Azathioprine30$1,187
Spironolactone75$691
Easy Touch Pen NeedlePen Needle, Diabetic20$568
Pantoprazole Sodium125$559

Paid to pharmacies, not to this prescriber.

Other hepatology in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →